Novartis Stock Price, Forecast & Analysis (NYSE:NVS)

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Novartis declared an annual dividend on Thursday, January 31st. Stockholders of record on Tuesday, March 5th will be paid a dividend of $2.8646 per share on Wednesday, March 13th. This represents a dividend yield of 3.27%. The ex-dividend date is Monday, March 4th. This is a boost from Novartis's previous annual dividend of $2.33. View Novartis' Dividend History.

Novartis AG (NYSE:NVS) announced its earnings results on Tuesday, October, 22nd. The company reported $1.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.31 by $0.10. The company had revenue of $12.17 billion for the quarter, compared to analysts' expectations of $11.67 billion. Novartis had a net margin of 24.43% and a return on equity of 20.86%. The firm's revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.32 earnings per share. View Novartis' Earnings History.

Novartis is scheduled to release their next quarterly earnings announcement on Wednesday, January 29th 2020. View Earnings Estimates for Novartis.

10 brokers have issued 1-year target prices for Novartis' shares. Their forecasts range from $79.16 to $105.00. On average, they expect Novartis' share price to reach $94.34 in the next year. This suggests a possible upside of 4.8% from the stock's current price. View Analyst Price Targets for Novartis.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 4 sell ratings, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.

Media coverage about NVS stock has trended very negative recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novartis earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Novartis.

Novartis saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 3,310,000 shares, an increase of 6.4% from the September 15th total of 3,110,000 shares. Based on an average daily trading volume, of 1,810,000 shares, the short-interest ratio is presently 1.8 days. Currently, 0.1% of the shares of the stock are short sold. View Novartis' Current Options Chain.

Some companies that are related to Novartis include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AbbVie (ABBV), AstraZeneca (AZN), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), AT&T (T), Cisco Systems (CSCO), NVIDIA (NVDA), Merck & Co., Inc. (MRK) and Verizon Communications (VZ).

Novartis' stock is owned by many different of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.36%), Manning & Napier Group LLC (0.11%), Bristol John W & Co. Inc. NY (0.03%), Envestnet Asset Management Inc. (0.03%), First Trust Advisors LP (0.02%) and Tocqueville Asset Management L.P. (0.02%).

NVS stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Thomasville National Bank, Carillon Tower Advisers Inc., Manning & Napier Group LLC, SG Americas Securities LLC, Matthew Goff Investment Advisor LLC, Scout Investments Inc. and Russell Investments Group Ltd..

NVS stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Renaissance Group LLC, First Trust Advisors LP, Envestnet Asset Management Inc., CWM LLC, Ferguson Wellman Capital Management Inc., CIBC Private Wealth Group LLC and Confluence Investment Management LLC.

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVS stock can currently be purchased for approximately $90.04.

Novartis has a market capitalization of $206.35 billion and generates $51.90 billion in revenue each year. The company earns $12.61 billion in net income (profit) each year or $5.09 on an earnings per share basis. Novartis employs 125,161 workers across the globe.View Additional Information About Novartis.

The official website for Novartis is http://www.novartis.com/.

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 011-41-61-324-1111 or via email at [email protected]